Title: A phase 3 randomised trial of Lenalidomide and Dexamethasone with or without Elotuzumab in Relapsed or Refractory Multiple Myeloma.
Population: Patients who have had 1-3 prior lines of treatment.
May have had bortezomib or thalidomide.
Can only have had Lenalidomide if:
– Achieved at least Partial response
– Had max 9 cycles
– Are not refractory (no Progessive Disease within 9 months).
Resource Links« Back